Skip to Main Content
LICENSES AND NOTICES

License for Use of "Physicians' Current Procedural Terminology", (CPT) Fourth Edition

End User/Point and Click Agreement: CPT codes, descriptions and other data only are copyright 2009 American Medical Association (AMA). All Rights Reserved (or such other date of publication of CPT). CPT is a trademark of the AMA.

You, your employees and agents are authorized to use CPT only as contained in the following authorized materials including but not limited to CGS fee schedules, general communications, Medicare Bulletin, and related materials internally within your organization within the United States for the sole use by yourself, employees, and agents. Use is limited to use in Medicare, Medicaid, or other programs administered by the Centers for Medicare & Medicaid Services (CMS). You agree to take all necessary steps to insure that your employees and agents abide by the terms of this agreement.

Any use not authorized herein is prohibited, including by way of illustration and not by way of limitation, making copies of CPT for resale and/or license, transferring copies of CPT to any party not bound by this agreement, creating any modified or derivative work of CPT, or making any commercial use of CPT. License to use CPT for any use not authorized here in must be obtained through the AMA, CPT Intellectual Property Services, 515 N. State Street, Chicago, IL 60610. Applications are available at the AMA websiteExternal Website.

This product includes CPT which is commercial technical data and/or computer data bases and/or commercial computer software and/or commercial computer software documentation, as applicable which were developed exclusively at private expense by the American Medical Association, 515 North State Street, Chicago, Illinois, 60610. U.S. Government rights to use, modify, reproduce, release, perform, display, or disclose these technical data and/or computer data bases and/or computer software and/or computer software documentation are subject to the limited rights restrictions of DFARS 252.227-7015(b)(2)(June 1995) and/or subject to the restrictions of DFARS 227.7202-1(a)(June 1995) and DFARS 227.7202-3(a)June 1995), as applicable for U.S. Department of Defense procurements and the limited rights restrictions of FAR 52.227-14 (June 1987) and/or subject to the restricted rights provisions of FAR 52.227-14 (June 1987) and FAR 52.227-19 (June 1987), as applicable, and any applicable agency FAR Supplements, for non-Department Federal procurements.

AMA Disclaimer of Warranties and Liabilities.

CPT is provided "as is" without warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability and fitness for a particular purpose. AMA warrants that due to the nature of CPT, it does not manipulate or process dates, therefore there is no Year 2000 issue with CPT. AMA disclaims responsibility for any errors in CPT that may arise as a result of CPT being used in conjunction with any software and/or hardware system that is not Year 2000 compliant. No fee schedules, basic unit, relative values or related listings are included in CPT. The AMA does not directly or indirectly practice medicine or dispense medical services. The responsibility for the content of this file/product is with CGS or the CMS and no endorsement by the AMA is intended or implied. The AMA disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this file/product. This Agreement will terminate upon notice if you violate its terms. The AMA is a third party beneficiary to this Agreement.

CMS Disclaimer

The scope of this license is determined by the AMA, the copyright holder. Any questions pertaining to the license or use of the CPT must be addressed to the AMA. End Users do not act for or on behalf of the CMS. CMS DISCLAIMS RESPONSIBILITY FOR ANY LIABILITY ATTRIBUTABLE TO END USER USE OF THE CPT. CMS WILL NOT BE LIABLE FOR ANY CLAIMS ATTRIBUTABLE TO ANY ERRORS, OMISSIONS, OR OTHER INACCURACIES IN THE INFORMATION OR MATERIAL CONTAINED ON THIS PAGE. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

This license will terminate upon notice to you if you violate the terms of this license. The AMA is a third party beneficiary to this license.

POINT AND CLICK LICENSE FOR USE OF "CURRENT DENTAL TERMINOLOGY", ("CDT")

End User License Agreement

These materials contain Current Dental Terminology, Fourth Edition (CDT), copyright © 2002, 2004 American Dental Association (ADA). All rights reserved. CDT is a trademark of the ADA.

THE LICENSE GRANTED HEREIN IS EXPRESSLY CONDITIONED UPON YOUR ACCEPTANCE OF ALL TERMS AND CONDITIONS CONTAINED IN THIS AGREEMENT. BY CLICKING BELOW ON THE BUTTON LABELED "I ACCEPT", YOU HEREBY ACKNOWLEDGE THAT YOU HAVE READ, UNDERSTOOD AND AGREED TO ALL TERMS AND CONDITIONS SET FORTH IN THIS AGREEMENT.

IF YOU DO NOT AGREE WITH ALL TERMS AND CONDITIONS SET FORTH HEREIN, CLICK BELOW ON THE BUTTON LABELED "I DO NOT ACCEPT" AND EXIT FROM THIS COMPUTER SCREEN.

IF YOU ARE ACTING ON BEHALF OF AN ORGANIZATION, YOU REPRESENT THAT YOU ARE AUTHORIZED TO ACT ON BEHALF OF SUCH ORGANIZATION AND THAT YOUR ACCEPTANCE OF THE TERMS OF THIS AGREEMENT CREATES A LEGALLY ENFORCEABLE OBLIGATION OF THE ORGANIZATION. AS USED HEREIN, "YOU" AND "YOUR" REFER TO YOU AND ANY ORGANIZATION ON BEHALF OF WHICH YOU ARE ACTING.

  1. Subject to the terms and conditions contained in this Agreement, you, your employees, and agents are authorized to use CDT-4 only as contained in the following authorized materials and solely for internal use by yourself, employees and agents within your organization within the United States and its territories. Use of CDT-4 is limited to use in programs administered by Centers for Medicare & Medicaid Services (CMS). You agree to take all necessary steps to ensure that your employees and agents abide by the terms of this agreement. You acknowledge that the ADA holds all copyright, trademark and other rights in CDT-4. You shall not remove, alter, or obscure any ADA copyright notices or other proprietary rights notices included in the materials.
  2. Any use not authorized herein is prohibited, including by way of illustration and not by way of limitation, making copies of CDT-4 for resale and/or license, transferring copies of CDT-4 to any party not bound by this agreement, creating any modified or derivative work of CDT-4, or making any commercial use of CDT-4. License to use CDT-4 for any use not authorized herein must be obtained through the American Dental Association, 211 East Chicago Avenue, Chicago, IL 60611. Applications are available at the American Dental Association websiteExternal Website.
  3. Applicable Federal Acquisition Regulation Clauses (FARS)\Department of Defense Federal Acquisition Regulation Supplement (DFARS) Restrictions Apply to Government use. Please click here to see all U.S. Government Rights Provisions.
  4. ADA DISCLAIMER OF WARRANTIES AND LIABILITIES. CDT-4 is provided "as is" without warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability and fitness for a particular purpose. No fee schedules, basic unit, relative values or related listings are included in CDT-4. The ADA does not directly or indirectly practice medicine or dispense dental services. The sole responsibility for the software, including any CDT-4 and other content contained therein, is with (insert name of applicable entity) or the CMS; and no endorsement by the ADA is intended or implied. The ADA expressly disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this file/product. This Agreement will terminate upon notice to you if you violate the terms of this Agreement. The ADA is a third-party beneficiary to this Agreement.
  5. CMS DISCLAIMER. The scope of this license is determined by the ADA, the copyright holder. Any questions pertaining to the license or use of the CDT-4 should be addressed to the ADA. End users do not act for or on behalf of the CMS. CMS DISCLAIMS RESPONSIBILITY FOR ANY LIABILITY ATTRIBUTABLE TO END USER USE OF THE CDT-4. CMS WILL NOT BE LIABLE FOR ANY CLAIMS ATTRIBUTABLE TO ANY ERRORS, OMISSIONS, OR OTHER INACCURACIES IN THE INFORMATION OR MATERIAL COVERED BY THIS LICENSE. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

The license granted herein is expressly conditioned upon your acceptance of all terms and conditions contained in this agreement. If the foregoing terms and conditions are acceptable to you, please indicate your agreement by clicking below on the button labeled "I ACCEPT". If you do not agree to the terms and conditions, you may not access or use the software. Instead, you must click below on the button labeled "I DO NOT ACCEPT" and exit from this computer screen.


Impact

Print | Bookmark | Email | Font Size: + |

LCD / Medical Policies Stakeholder Meetings

Compliance Officer Meetings

Closed to members & invited guests

State

Date/Time

Location

J15 KY/OH

February 13, 2024
2:30 – 3:30 PM ET

Microsoft Teams

J15 KY/OH

June 18, 2024
2:30 – 3:30 PM ET

The Christ Hospital
Main Campus Auditorium
2139 Auburn Avenue
Cincinnati, OH 45219

J15 KY

October 29, 2024
2:30 – 3:30 PM ET

Norton Women's & Children's Hospital
Medical Plaza 1
Ground Floor, LLD Conference Room
3999 Dutchmans Lane
Louisville, KY 40207

J15 OH

October 30, 2024
2:30 – 3:30 PM ET

OSU Wexler Medical Center
Biomedical Research Tower
460 W 12th Ave
Room 105 – 1st Floor
Columbus, OH 43210

Contractor Advisory Committee (CAC) Meetings

CAC meetings are for the purpose of discussing literature related to proposed Local Coverage Determinations (LCDs) before they're developed.

CAC members serve in an advisory capacity. All meetings are open to the public to attend and observe.

State

Date/Time

Location

Agenda

Documentation

Multi-Jurisdictional CAC Meeting (hosted by Palmetto GBA)

February 3, 2025
2-4 PM ET

Microsoft Teams Webinar

Registration:

Topic: Peripheral Nerve Blocks and Ablations

 

Multi-Jurisdictional Host: National Government Services

October 17, 2024
3-5 PM ET

Webex

RegistrationExternal Website

Topic: Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC)

Transcript and RecordingsExternal Website

Multi-Jurisdictional Host: Palmetto GBA

July 15, 2024
2-4 PM ET

Microsoft Teams

Topics: MolDX: Biomarker Risk Stratification Testing in DCIS

Transcript and RecordingsExternal Website

See Prior CAC Meetings below.

Open Meetings

Open Meetings are for the purpose of discussing new proposed (draft) LCDs and/or the revised portion of a proposed LCD in the 45-day open comment period. These meetings are not a forum to discuss specific claims, the submission of new drugs or indications, or to market forthcoming drugs or medical devices.

Open to the public

State

Date/Time

Location

Agenda

Documentation

J15 KY/OH

February 13, 2024
4-5 PM ET

Microsoft Teams

Topics:

  • DL38773 – Facet Joint Interventions for Pain Management
  • DA58364 – Billing and Coding: Facet Joint Interventions for Pain Management
  • DL39741 – Cervical Fusion
  • DA59608 – Billing and Coding: Cervical Fusion

Proposed/Draft LCDs not released to final:

J15 KY/OH

May 16, 2024
3-5 PM ET

Microsoft Teams

Topics:

  • DL39756/DA59618 – Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers
  • DL39802/DA59682 – Minimally Invasive Arthrodesis of the Sacroiliac Joint (SIJ)

Proposed/Draft LCDs not released to final:

J15 KY/OH

June 18, 2024
4-5 PM ET

The Christ Hospital
Main Campus Auditorium
2139 Auburn Avenue
Cincinnati, OH 45219

and

Microsoft Teams

Topics:

  • DL37578/DA56491 – MIGS
  • DL39857/DA59726 – Botulinum Toxins
  • DL39840/DA59716 – Quantitative Coronary Plaque Analysis derived from Artificial Intelligence Enabled CT Based Quantitative Coronary Topography (AI-QTC)/Coronary Plaque Analysis (AI-CPA)

Proposed/Draft LCDs not released to final:

J15 KY

October 29, 2024
4-5 PM ET

Marshall Women's Health & Education Center
4123 Dutchmans Lane
Medical Plaza 1
Ground Floor, LLD Conference Room
Louisville, KY 40207

and Microsoft Teams

To attend via Microsoft Teams, you must registerExternal Website.

Topics:

  • MolDX: Genetic Testing for Heritable Thoracic Aortic Disease (DL39938/DA59860)
  • MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms (DL4000/DA59919)
  • MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis (DL39940/DA59862)
  • Intravertebral Disc Injections (Via Disc) 0627T (DL39958/DA59880)
  • Non-invasive Vascular (open to revised section only) (DL34045/DA56697)

Proposed/Draft LCDs not released to final:

J15 OH

October 30, 2024
4-5 PM ET

OSU Wexler Medical Center
Biomedical Research Tower
460 W 12th Ave
Room 105 – 1st Floor
Columbus, OH 43210

and Microsoft Teams

To attend via Microsoft Teams, you must registerExternal Website.

Topics:

  • MolDX: Genetic Testing for Heritable Thoracic Aortic Disease (DL39938/DA59860)
  • MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms (DL4000/DA59919)
  • MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis (DL39940/DA59862)
  • Intravertebral Disc Injections (Via Disc) 0627T (DL39958/DA59880)
  • Non-invasive Vascular (open to revised section only) (DL34045/DA56697)

Proposed/Draft LCDs not released to final:

See Prior Open Meetings below.

Provider Touch Point Meetings

Closed to members & invited guests

State

Date/Time

Location

J15 KY/OH

February 13, 2024
6 – 7 PM ET

Microsoft Teams

J15 KY/OH

June 18, 2024
6 – 7 PM ET

The Christ Hospital
Main Campus Auditorium
2139 Auburn Avenue
Cincinnati, OH 45219

J15 KY

October 29, 2024
6 – 7 PM ET

Norton Women's & Children's Hospital
Medical Plaza 1
Ground Floor, LLD Conference Room
3999 Dutchmans Lane
Louisville, KY 40207

J15 OH

October 30, 2024
6 – 7 PM ET

OSU Wexler Medical Center
Biomedical Research Tower
460 W 12th Ave
Room 105 – 1st Floor
Columbus, OH 43210

Prior CAC Meetings

Date Topic Details Documentation

10.19.2023

Botulinum Toxins

08.16.2023

Cervical Fusion

05.25.2023

Non-Invasive Technology for Coronary Artery Plaque Analysis

04.27.2023

Trigger Point Injections

  • Multi-Jurisdictional Host: WPS Government Health Administrators (GHA)

02.28.2023

RPM and RTM for Non-Implantable Devices

  • Multi-Jurisdictional Host: Novitas and First Coast Service Options

01.05.2023

Micro-Invasive Glaucoma Surgery (MIGS)

11.09.2022

PET Scans for Inflammation and Infection

03.10.2022

Sacroiliac Joint Injections and Procedures

12.07.2021

MolDX: Predictive Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis

10.12.2021

MolDX: Molecular Testing for Risk Stratification of Upper Gastrointestinal Cancer

09.29.2021

Transcranial Magnetic Stimulation (TMS) for Obsessive-Compulsive Disorder (OCD)

05.12.2021

Amniotic Product Injections for Musculoskeletal Indications, Non-Wound

03.10.2021

Platelet Rich Plasma for Non-Wound Care

02.11.2021

Epidural Interventions for Chronic Pain Management

01.11.2021

Molecular Diagnostic Testing for Pathogens

11.18.2020

Electroretinography

 

05.28.2020

Facet Joint and Medical Nerve Branch Procedures

 

06.29.2019

Pharmacogenomics

 

03.20.2019

Vertebral Augmentation

 

Prior Open Meetings

State Date Topics Documentation

J15 OH

11.08.2023

  • MolDX: Gene Expression Profile Tests for Decision-Making in Castration Resistant and Metastatic Prostate Cancers
  • MolDX: Molecular Biomarkers for Risk Stratification of Indeterminate Pulmonary Nodules Following Bronchoscopy
  • MolDX: Molecular Testing for Risk Stratification of Thyroid Nodules
  • MolDX: Molecular Testing for Solid Organ Allograft Rejection
  • Implantable Continuous Glucose Monitors (I-CGM)
  • Trigger Point Injections (TPI)

J15 KY

11.07.2023

  • MolDX: Gene Expression Profile Tests for Decision-Making in Castration Resistant and Metastatic Prostate Cancers
  • MolDX: Molecular Biomarkers for Risk Stratification of Indeterminate Pulmonary Nodules Following Bronchoscopy
  • MolDX: Molecular Testing for Risk Stratification of Thyroid Nodules
  • MolDX: Molecular Testing for Solid Organ Allograft Rejection
  • Implantable Continuous Glucose Monitors (I-CGM)
  • Trigger Point Injections (TPI)

J15 KY/OH

07.11.2023

  • Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound
  • Fluid Jet System in the Treatment of Benign Prostatic Hyperplasia (BPH)
  • Micro-Invasive Glaucoma Surgery (MIGS)MolDX: Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma

J15 KY/OH

06.22.2023

Urinary Biomarkers for Chronic Pain Management

J15 KY/OH

05.17.2023

Urine Drug Testing

J15 KY/OH

02.21.2023

  • Cosmetic and Reconstructive Surgery
  • Positron Emission Tomography (PET) for Inflammation and Infection Special Histochemical Stains and Immunohistochemical Stains
  • Transthoracic Echocardiography (TTE)

J15 OH

10.26.2022

  • Allogenic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin
  • MolDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma
  • MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis
  • Sacroiliac Joint Injections and Procedures
  • Skin Substitutes for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers
  • Transtelephonic Spirometry
  • Urine Drug Testing

J15 KY

10.25.2022

  • Allogenic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin
  • MolDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma
  • MolDX: Molecular Biomarker Testing to Guide Targeted Therapy Selection in Rheumatoid Arthritis
  • Sacroiliac Joint Injections and Procedures
  • Skin Substitutes for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers
  • Transtelephonic Spirometry
  • Urine Drug Testing

J15 KY/OH

06.21.2022

  • MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia and Neoplasia
  • MolDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer
  • Prostate Cancer Detection with IsoPSA™
  • Transcranial Magnetic Stimulation (TMS)

J15 KY/OH

02.22.2022

Non-Invasive Fractional Flow Reserve (FFR) for Stable Ischemic Heart Disease

J15 KY/OH

10.13.2021

  • Colon Capsule Endoscopy (CCE)
  • Prostate Cancer Detection with IsoPSA™

J15 KY/OH

07.13.2021

  • Epidural Procedures for Pain Management
  • MolDX: Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer
  • MolDX: Melanoma Risk Stratification Molecular Testing
  • MolDX: Multiplex Nucleic Acid Amplification Test (NAAT) Panels for Infectious Disease Testing
  • MolDX: Next-Generation Sequencing Lab-Developed Tests for Inherited Cancer Syndromes

J15 KY/OH

02.23.2021

  • Off-Label Use of Rituximab and Rituximab Biosimilars
  • Percutaneous Vertebral Augmentation (PVA) for Osteoporotic Vertebral Compression Fracture (VCF)

J15 KY/OH

10.13.2020

Non-Invasive Flow Reserve (FFR) for Stable Ischemic Heart Disease

J15 KY/OH

10.13.2020

  • Colon Capsule Endoscopy (CCE)
  • Controlled Substance Monitoring and Drugs of Abuse Testing
  • Magnetic Resonance Guided Focused Ultrasound Surgery System (MRgFUS) for the Treatment of Neurologic Conditions
  • MolDX: Minimal Residual Disease Testing (MRDT) for Cancer

J15 KY/OH

10.13.2020

Facet Joint Interventions for Pain Management

J15 KY/OH

02.18.2020

Vitamin D Assay Testing (L33996) Reconsideration

J15 OH

10.30.2019

Open Draft/Revised LCD Discussion

J15 KY

10.29.2019

Open Draft/Revised LCD Discussion

J15 KY/OH

06.18.2019

Open Draft/Revised LCD Discussion

J15 KY/OH

05.07.2019

Drug Interaction Testing and Multiple MolDX Draft Policies

J15 KY/OH

02.12.2019

MolDX: DecisionDx – Melanoma

spacer

26 Century Blvd Ste ST610, Nashville, TN 37214-3685 © 2025 CGS Administrators, LLC. All Rights Reserved